AI Article Synopsis
Article Abstract
Macroprolactinemia, due to increased circulating levels of large molecular weight forms of prolactin, results in elevated level of immuno-reactive prolactin. The big variants have only weak biological activity; thus macroprolactinemia appears as a case of hyperprolactinemia without clinical significance as demonstrated by the five patients described. The diagnosis is based upon chromatography which separates the hormone and its variants. This disorder produces a pitfall in the diagnostic evaluation of hyperprolactinemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0248-8663(97)84018-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Laboratory diagnostic methods are the main tools in the practice of a doctor of any specialty, including an endocrinologist. Factors were identified that could change the concentration of the biologically active fraction of the test substance, subsequently complicating the interpretation of laboratory results and making the right clinical decision. The literature describes a variety of circulating autoantibodies involved in binding to pituitary hormones (prolactin (PRL), thyroid-stimulating hormone (TSH), growth hormone, luteinizing, follicle-stimulating, and adrenocorticotropic hormones), hypothalamus (vasopressin and oxytocin), pancreas (insulin and glucagon) , parathyroid glands (parathyroid hormone), as well as with thyroid hormones.
View Article and Find Full Text PDFTumor-grade hyperprolactinemia induced by multiple medications in the setting of renal failure.
Endocr Pract
April 2005
Division of Endocrinology, Diabetes and Metabolism, Washington University School of Medicine, St. Louis, Missouri, USA.
Objective: To describe a patient with galactorrhea and severe hyperprolactinemia in whom workup revealed a nontumoral mechanism.
Methods: We present the medical history of a woman with long-standing diabetes in whom bilateral galactorrhea and hyperprolactinemia developed. In addition, the details of her clinical course and management are reviewed.
Clinical and biological characterization of macroprolactinemia with and without prolactin-IgG complexes.
Eur J Endocrinol
September 2003
Department of Endocrinology, Hospital VUB, Brussels, Belgium.
Objective: Macroprolactinemia, which can be detected by a polyethylene glycol (PEG) precipitation test, is a clinically and biologically heterogeneous condition. In this study, we analyzed whether the clinical presentation, the hormonal findings and the in vitro lactogenic activity differed between macroprolactinemic patients with and without circulating prolactin (PRL)-IgG complexes.
Design: Clinical data were reviewed and additional hormonal studies were performed in 50 hyperprolactinemic patients with macroprolactinemia.
[Macroprolactinemia, a variety of hyperprolactinemia. Apropos of 5 cases].
Rev Med Interne
June 1997
Service d'endocrinologie, hôpital Pasteur, CHU, Nice, France.
Macroprolactinemia, due to increased circulating levels of large molecular weight forms of prolactin, results in elevated level of immuno-reactive prolactin. The big variants have only weak biological activity; thus macroprolactinemia appears as a case of hyperprolactinemia without clinical significance as demonstrated by the five patients described. The diagnosis is based upon chromatography which separates the hormone and its variants.
View Article and Find Full Text PDFControl of prolactin secretion.
Klin Wochenschr
December 1990
Abteilung für Endokrinologie, Medizinische Klinik und Poliklinik, Universität Essen.
1. Prolactin is a 21,500 Dalton single-chain polypeptide hormone but may occur in 50 kDa and 150 kDa molecular variants. 2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!